HCG Manavata Cancer Centre, Nashik
19 years of experience
MS , Basic Surgical Skills (BSS) Royal College of Surgeons , DNB
Dr Rajnish Nagarkar completed his graduation at a reputed college in Belgaum, Karnataka, after which he went on to pursue his MS at a prestigious institute in Mumbai, followed by BSS from Royal College of Surgeons, Edinburgh, and DNB from New Delhi. Dr Nagarkar has 17 years of experience in the field of Oncology and in this period, he has authored multiple books and journals. His papers and presentations have also been published in various publications, both nationally and internationally. He is also a recipient of various awards at the National level.
MBBS from Jawaharlal Nehru Medical College , Belgaum; 1996 MS from Tata Memorial Hospital, Mumbai; 2000 BSS from Royal College of Surgeons, Edinburgh; 2000 DNB from Ministry of Health, New Delhi; 2000 Membership of Royal college of Surgeons, Edinburgh (MRCSEd) Royal College of Surgeons, Edinburgh; 2000 Membership of National Academy of Medical Sciences (MNAMS) Ministry of Health, New Delhi; 2004 ICH-GCP Training in Various Investigators Meetings
Managing Director & Chief Surgical Oncologist,HCG Manavata Cancer Centre,May 2007 Р Present
Maharashtra Oncology Group
Breast Cancer, Gastrointestinal (GI) Cancer.
Palwe, Vijay & Nagarkar, Rajnish. (2013). TACE plus sorafenib for the treatment of advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 31. e15178-e15178. https://doi.org/10.1200/jco.2013.31.15_suppl.e15178 Poveda, Andres & Oza, Amit & Fabbro, Michel & Redondo, AndrЋs & Bamias, Aristotle & Covens, Al & Romero, Ignacio & Bae, Duk-Soo & Censi, Andrea & Nagarkar, Rajnish & Richardson, Gary & Gallardo-Rinc—n, Dolores & Rasmussen, Erik & Rossi, John & Bass, Michael & Warner, Douglas & Monk, Bradley. (2014). Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free survival (PFS) in TRINOVA-1.. Journal of Clinical Oncology. 32. 5542-5542. https://doi.org/10.1200/jco.2014.32.15_suppl.5542 Ahmad, Ateeq & Sheikh, Saifuddin & Mehta, Ajay & Nagarkar, Rajnish & Srinivasan, Krishnan & Majumdar, Anup & Mukherjee, Kalyan & Singh, Jitendra & Shrivastav, SP & Thungappa, Satheesh & Maksud, Tanveer & Pawar, Suraj & Sonawane, Satish & Kamat, Satish & Sharma, Manish & Rane, R. & Ahmad, Imran. (2014). Cremophor EL-free formulation of paclitaxel: A randomized, multicenter, safety, and efficacy study of nanosomal paclitaxel lipid suspension (NPLS) versus paclitaxel in women with metastatic breast cancer (MBC).. Journal of Clinical Oncology. 32. 573-573. https://doi.org/10.1200/jco.2014.32.15_suppl.573 Im, Young-Hyuck & Uslu, RџЌhan & Lee, Keun Seok & Nagarkar, Rajnish & Sohn, Joohyuk & Sevinc, Alper & Altundag, Kadri & Chang, Yuan-Ching & Abdel-Razeq, Hikmat & Im, Seock-Ah & Jeong, Joon & Park, Ho & Arpornwirat, Wichit & Bastick, Patricia & Le, Tuan & Arikan, Ozlem & Xue, Hong-Ling & Canatar, Aycin & Valenti, Roberta & Kim, Sung-Bae. (2015). Clinical effectiveness of Everolimus and Exemestane in advanced breast cancer patients from Asia and Africa: First efficacy and updated safety results from the phase IIIb EVEREXES study.. Journal of Clinical Oncology. 33. e11579-e11579. https://doi.org/10.1200/jco.2015.33.15_suppl.e11579 Soulieres, Denis & Faivre, Sandrine & Mesia, R. & Remenar, Eva & Li, Shau-Hsuan & Karpenko, Andrey & Dechaphunkul, Arunee & Kiss, Laura & Lin, Jin-Ching & Nagarkar, Rajnish & Tamas, Laszlo & Kim, Sung-Bae & Erf‡n, Jozsef & Turri, Sabine & Dey, Debarshi & Chakravartty, Arunava & Aimone, Paola & Massacesi, Cristian & Licitra, Lisa. (2016). BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology. 34. 6008-6008. https://doi.org/10.1200/JCO.2016.34.15_suppl.6008 Viswabandya, Auro & Mukhopadhyay, Asis & Shah, Sandip & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2016). Comparison of Pharmacokinetics and Pharmacodynamics of Two Anti-CD20 Monoclonal Antibodies (Candidate Biosimilar DRL-Rituximab and Innovator Reference Product Rituximab (MabtheraЁ) in a Randomised, Multi-Centre, Double-Blind, Parallel Group Study of CHOP with Rituximab Chemotherapy in Patients with CD20-Positive Diffuse Large B-Cell Lymphoma. Blood. 128. 5391-5391. https://doi.org/10.1182/blood.V128.22.5391.5391 Shah, Sandip & Viswabandya, Auro & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2017). Comparative double-blind randomized trial of 2 rituximab products in patients with CD20+ diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology. 35. 7550-7550. https://doi.org/10.1200/JCO.2017.35.15_suppl.755 Viswabandya, Auro & Shah, Sandip & Mukhopadhyay, Asis & Nagarkar, Rajnish & Batra, Sonica & Lopez-Lazaro, Luis & Kankanwadi, Suresh & Srivastava, Alok. (2019). Randomized, Double-Blind, Pharmacokinetic Equivalence Trial Comparing DRL-Rituximab With MabThera in Patients With Diffuse Large B-Cell Lymphoma. Journal of Global Oncology. 5. 1-13. https://doi.org/10.1200/JGO.19.00248
Breast Cancer, Gastrointestinal (GI) Cancer.